Izon's qEV isolation and TRPS/NPS single-particle measurement technology is cited in a continually growing body of peer-reviewed research — from extracellular vesicle biomarker discovery to cancer diagnostics, cardiovascular biology, and infectious disease. A curated selection is below.
Figures reflect Izon Science's global publications database. See izon.com/publications for the complete, continually updated list.
The papers that established qEV and TRPS as validated methods in the field, alongside recent work from Harvard Medical School's research centres.
The original single-step SEC protocol for isolating EVs from body fluids — the method Izon's qEV column directly commercializes. One of the most-cited papers in the EV isolation field. (Amsterdam UMC)
Read the paper →Established TRPS as a reproducible way to size and count individual EVs, resolving the pore-to-pore variability that had limited earlier single-particle methods. (Amsterdam UMC)
Read the paper →Six independent labs across four countries jointly validated a standardized TRPS protocol for EV concentration measurement, using qEV-isolated plasma EVs as the reference material. (University of Queensland, Duke University, Erasmus MC, Aarhus University, La Trobe University)
Read the paper →The International Society for Extracellular Vesicles' formal position statement on best-practice EV research, naming SEC (qEV) and TRPS among the accepted isolation and measurement methods. One of the most-cited papers in EV science.
Read the paper →Compares 20 nm and 35 nm qEV pore sizes for EV yield and purity, from the Cardiovascular Research Center at Massachusetts General Hospital, Harvard Medical School, with Johns Hopkins and Drexel University co-authors.
Read the paper →Evaluates multimode chromatography techniques for high-purity EV isolation from human plasma, from Harvard Medical School's Nano Flow Core Facility at Beth Israel Deaconess Medical Center.
Read the paper →Uses TRPS to characterize an LNP-delivered siRNA therapeutic candidate against SARS-CoV-2, published in the high-impact gene- and cell-therapy journal Molecular Therapy. (Griffith University, Australia)
Read the paper →Benchmarks qEV columns against eight other EV isolation methods for proteomic yield and purity from just 100 µL of human plasma. (University of North Carolina at Greensboro)
Read the paper →Uses TRPS to characterize magnetically targeted, ultrasound-triggered liposomes carrying an anti-vascular cancer drug, developed by CNRS and INSERM's Paris research consortium.
Read the paper →Lipid nanoparticles and virus-like particles now represent a larger and faster-growing market than extracellular vesicles alone — spanning mRNA vaccines, gene editing, gene therapy, and next-generation vaccine platforms.
An antibody-targeted LNP, purified using qEV columns, delivers RNA and mRNA directly to blood stem cells in living rodents — achieving gene editing in roughly 90% of hematopoietic stem and progenitor cells from a single injection. (MIT, Koch Institute for Integrative Cancer Research)
Read the paper →TRPS confirmed that a multi-antigen VLP vaccine candidate matched the size of the authentic SARS-CoV-2 virion. The candidate has since advanced into a Phase I clinical trial (NCT04818281).
Read the paper →Uses TRPS to characterize an LNP-delivered siRNA therapeutic candidate against SARS-CoV-2, published in the high-impact gene- and cell-therapy journal Molecular Therapy. (Griffith University, Australia)
Read the paper →TRPS was used alongside other biophysical methods across six Influenza VLP variants (groups A and B, monovalent and pentavalent) to monitor consistency during vaccine manufacturing. (iBET, Portugal)
Read the paper →TRPS measured particle-size distribution to guide continuous-chromatography purification of an oncolytic adenovirus, improving productivity and robustness for gene-therapy manufacturing.
Read the paper →Uses qEV columns to separate drug-loaded liposomes from free drug, assessing the entrapment capacity and shelf-life stability of steroid-carrying liposomes for anti-inflammatory delivery.
Read the paper →Uses TRPS to characterize magnetically targeted, ultrasound-triggered liposomes carrying an anti-vascular cancer drug, developed by CNRS and INSERM's Paris research consortium.
Read the paper →Used qEV isolation to remove unbound antibody and the majority of Hepatitis B virions from plasma, opening the door to functional studies that separate EVs from co-isolated virus particles.
Read the paper →Method-comparison studies that validate SEC as a reliable, reproducible way to isolate EVs — the groundwork every application-specific study downstream depends on.
Benchmarks SEC against ultracentrifugation, precipitation, and immunoaffinity capture from a clinically realistic 1 mL plasma volume — finding SEC delivers the best combination of particle yield, purity, and downstream proteomic usability.
Read the paper →Compares recovery and separation efficiency across ten different SEC columns, showing resin pore size is a key variable that downstream miRNA biomarker studies need to control for.
Read the paper →Directly compares UF-SEC with sucrose-cushion ultracentrifugation across three myeloma cell lines and patient plasma, reporting more consistent, higher-yield EV recovery with SEC.
Read the paper →As EV- and MSC-EV-based therapeutics move toward clinical manufacturing, isolation methods need to scale without sacrificing purity or function — an area qEV columns are increasingly benchmarked against.
Benchmarks qEV against other isolation kits for extracting EVs from cow milk — a large-volume, industrially relevant biofluid outside the plasma and urine samples most isolation studies focus on.
Read the paper →Compares five isolation methods, including qEV, across recovery, purity, and subcellular origin — helping manufacturers match the right isolation approach to the intended clinical application.
Read the paper →A foundational scale-up study combining ultrafiltration with SEC for high-yield EV isolation that preserves biophysical and functional properties — still widely cited in manufacturing protocols today.
Read the paper →Directly compares SEC- and ultracentrifugation-isolated EVs, showing SEC preserves EV functional activity better — key evidence for manufacturers replacing ultracentrifugation with column-based isolation at scale.
Read the paper →Uses Izon qEV10 columns to isolate exosomes from human adipose-derived stem cells (hADSC) and compares the resulting protein cargo across isolation methods.
Read the paper →Uses Izon qEV10/35 nm columns to compare large- and small-EV isolation from cardiac progenitor cells, informing isolation choices for cardiac regenerative applications.
Read the paper →From cartilage regeneration to wound healing, EV-based regenerative approaches are an emerging application area — including some of the newest work on plant-derived extracellular vesicles.
Uses a 35 nm qEV column to isolate grapefruit-derived exosome-like nanovesicles, evaluated as a candidate cartilage-regenerative treatment for early-stage osteoarthritis. (UCL, Royal National Orthopaedic Hospital)
Read the paper →Directly benchmarks qEV alongside tangential flow filtration, ultracentrifugation, and density-gradient ultracentrifugation for isolating lotus-derived EVs used in a wound-healing model. Tangential flow filtration gave the highest purity and yield in this particular study — an honest data point on when qEV is, and isn't, the top performer. (National Taiwan University)
Read the paper →EVs are emerging as liquid-biopsy biomarkers across cancer types — from blood-based screening tests to mechanistic studies of how tumors use EVs to spread.
Adds quality-control steps — including SEC-based EV isolation — to an miRNA liquid biopsy assay, moving a Hodgkin lymphoma treatment-response test closer to regulatory-grade clinical use.
Read the paper →Reports a tumour-EV blood test achieving 97% specificity and 97% sensitivity for high-grade serous carcinoma in an independent, blinded verification cohort of nearly 400 women.
Read the paper →Identifies an exosomal microRNA mechanism that reprograms liver cholesterol metabolism to support breast cancer metastasis, with antagomir treatment shown to block spread in a mouse model.
Read the paper →Uses long-term cultured brain organoids to show glioblastoma cells transfer material to healthy neural cells via extracellular vesicles — a mechanism that may help reprogram the tumour microenvironment.
Read the paper →EV biomarkers extend well beyond cancer, offering minimally invasive windows into neurodegenerative disease progression and vascular health.
Across a 704-patient cohort, plasma EV tau and TDP-43 levels distinguish frontotemporal dementia and ALS subtypes with high accuracy — a minimally invasive alternative to current diagnostic pathways.
Read the paper →Shows blood-vessel regions exposed to low shear stress — where atherosclerotic plaques typically form — take up far more endothelial EVs, pointing to an EV-driven mechanism in early vascular disease.
Read the paper →Shows EVs from healthy adult heart-muscle cells reduce fibrotic markers and improve heart function when injected into an animal model of cardiac fibrosis — a candidate cell-free therapy.
Read the paper →Extracellular vesicles both reveal how the body responds to infection and, in some cases, carry the virus particles themselves — two distinct angles qEV isolation supports.
Tracks EV spike and nucleocapsid protein levels across 39 severe COVID-19 patients over time, linking higher EV viral-protein expression to poorer antibody response and worse clinical outcomes.
Read the paper →Used qEV isolation to remove unbound antibody and the majority of Hepatitis B virions from plasma, opening the door to functional studies that separate EVs from co-isolated virus particles.
Read the paper →